Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.49 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.48 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717369 | 0.81 | HPRT1 (0.42) | PNPHPRT1ADCY5ADORA3 | |
| SCHEMBL6717375 | 0.81 | HPRT1 (0.42) | PNPHPRT1ADCY5ADORA3 | |
| SCHEMBL4851387 | 0.79 | ADCY5 (0.74) | ADCY5 | |
| SCHEMBL9471442 | 0.76 | ADORA3 (0.54) | PNPHPRT1ADORA3USP2TSHR | |
| SCHEMBL23721010 | 0.74 | HPRT1 (0.55) | PNPHPRT1ADCY5ADORA3USP2 | |
| SCHEMBL10394261 | 0.74 | HPRT1 (0.55) | PNPHPRT1ADCY5ADORA3USP2 | |
| SCHEMBL9308999 | 0.74 | PNP (0.59) | PNPHPRT1ADORA3USP2TSHR | |
| SCHEMBL9309114 | 0.74 | PNP (0.59) | PNPHPRT1ADORA3USP2TSHR | |
| SCHEMBL9309006 | 0.74 | PNP (0.59) | PNPHPRT1ADORA3USP2TSHR | |
| SCHEMBL600702 | 0.73 | ADORA3 (0.52) | PNPHPRT1ADORA3USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1049678-B1 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | SANOFI SA (FR) | 2012-10-24 | — | — | EP | claimed |
| US-7439345-B2 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| US-6689884-B1 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2004-02-10 | — | — | US | claimed |
| EP-1049678-A2 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | Nanogen Recognomics GmbH (DE) | 2000-11-08 | — | — | EP | claimed |
| WO-1999015509-A2 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | claimed |
| EP-1049678-B1 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | SANOFI SA (FR) | 2012-10-24 | — | — | EP | disclosed |
| US-7439345-B2 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20040142451-A1 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2004-07-22 | — | — | US | disclosed |
| US-6689884-B1 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2004-02-10 | — | — | US | disclosed |
| EP-1049678-A2 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | Nanogen Recognomics GmbH (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999015509-A2 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142451-A1 | Supramolecular pairing system, its preparation and use | TIMCC, MTCL3, UACA | PNP 4816/4885HPRT1 2316/4885ADCY5 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.